Hyun Ju Yoon

Hyun Ju Yoon

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2023 in European Heart Journal
Verified
Journal Article
Open access
PDF file
JCJae Yeong Cho
Jae Yeong Cho
KKKye Hun Kim
Kye Hun Kim
NLNuri Lee
Nuri Lee
SCSoo Hyeon Cho
Soo Hyeon Cho
SKSeung Yun Kim
Seung Yun Kim
JCJeong Gwan Cho
Jeong Gwan Cho
A comprehensive nationwide study on the incidence and outcomes of COVID-19 vaccination-related myocarditis (VRM) is in need. Among 44 276 704 individuals with at least 1 dose of COVID-19 vaccination, the incidence and clinical courses of VRM cases confirmed by the Expert Adjudication Committee of the Korea Disease Control and Prevention Agency were analyzed. COVID-19 VRM was confirmed in 480 cases (1.08 cases per 100 000 persons). Vaccination-related myocarditis incidence was significantly higher in men than in women (1.35 vs. 0.82 per 100 000 persons, P < 0.001) and in mRNA vaccines than in other vaccines (1.46 vs. 0.14 per 100 000 persons, P < 0.001). Vaccination-related myocarditis incidence was highest in males between the ages of 12 and 17 years (5.29 cases per 100 000 persons) and lowest in females over 70 years (0.16 cases per 100 000 persons). Severe VRM was identified in 95 cases (19.8% of total VRM, 0.22 per 100 000 vaccinated persons), 85 intensive care unit admission (17.7%), 36 fulminant myocarditis (7.5%), 21 extracorporeal membrane oxygenation therapy (4.4%), 21 deaths (4.4%), and 1 heart transplantation (0.2%). Eight out of 21 deaths were sudden cardiac death (SCD) attributable to VRM proved by an autopsy, and all cases of SCD attributable to VRM were aged under 45 years and received mRNA vaccines. Although COVID-19 VRM was rare and showed relatively favorable clinical courses, severe VRM was found in 19.8% of all VRM cases. Moreover, SCD should be closely monitored as a potentially fatal complication of COVID-19 vaccination. Study flowchart and summary of the percentage of patients with adverse outcomes among 480 cases of COVID-19 vaccination-related myocarditis. VRM, vaccine-related myocarditis; SCD, sudden cardiac death; ICU, intensive care unit; ECMO, extracorporeal membrane oxygenation

17 September 2024 in JACC: Cardiooncology
Verified
Journal Article
Open access
HPHyukjin Park
Hyukjin Park
NLNuri Lee
Nuri Lee
CHCho Hee Hwang
Cho Hee Hwang
SCSang-Geon Cho
Sang-Geon Cho
GCGa Hui Choi
Ga Hui Choi
YAYoungkeun Ahn
Youngkeun Ahn
The long-term prognosis after the discontinuation of cardioprotective therapy (CPT) in patients with cancer therapeutics–related cardiac dysfunction (CTRCD) that has shown improvement remains unclear. This study aims to assess the prognosis after CPT withdrawal in patients exhibiting improved CTRCD. In this retrospective analysis of a single-center prospective cohort study, patients with improved CTRCD, defined as an increase in left ventricular ejection fraction (LVEF) ≥10 percentage points from the time of CTRCD diagnosis, were included. We analyzed their clinical outcomes, which included hospitalization for heart failure or a decrease in LVEF ≥10 percentage points within 2 years after CTRCD improvement, alongside echocardiographic changes. The cohort comprised 134 patients with improved CTRCD. The median follow-up duration after CTRCD diagnosis was 368.3 days (Q1-Q3: 160-536 days). After improvement, 90 patients continued CPT (continued group [CG]) and 44 withdrew CPT (withdrawn group [WG]). Among patients whose baseline LVEF at CTRCD diagnosis ranged from 45% to 55%, the final mean LVEF was comparable between both groups (CG: 64.9% ± 4.4% vs WG: 62.9% ± 4.2%; P = 0.059). However, for patients with a baseline LVEF <45%, the final mean LVEF was significantly lower in the WG (CG: 53.3% ± 6.4% vs WG: 48.2% ± 6.9%; P < 0.001). The occurrence of composite major clinical events was notably higher in the WG (HR: 3.06; 95% CI: 1.51-7.73; P = 0.002). Patients who withdrew CPT after demonstrating improvement in CTRCD experienced worse clinical outcomes. Notably, a significant decrease in LVEF was observed after CPT withdrawal in patients with a baseline LVEF <45%.

1 January 2014 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
KLKi Hong Lee
Ki Hong Lee
YAYoungkeun Ahn
Youngkeun Ahn
SKSung Soo Kim
Sung Soo Kim
SRSi Hyun Rhew
Si Hyun Rhew
YJYoung Wook Jeong
Young Wook Jeong
KIKAMIR (Korea Acute Myocardial Infarction Registry) Investigators
KAMIR (Korea Acute Myocardial Infarction Registry) Investigators
Lee KH, et al. J Korean Med Sci. 2014 Apr;29(4):527-535. https://doi.org/10.3346/jkms.2014.29.4.527

1 January 2019 in Korean Circulation Journal
Verified
Journal Article
Open access
MKMin Chul Kim
Min Chul Kim
YAYoungkeun Ahn
Youngkeun Ahn
JCJae Yeong Cho
Jae Yeong Cho
KLKi Hong Lee
Ki Hong Lee
DSDoo Sun Sim
Doo Sun Sim
KSKi-Bae Seung
Ki-Bae Seung
Kim MC, et al. Korean Circ J. 2018 Aug;49:e35. https://doi.org/10.4070/kcj.2018.0341

1 January 2015 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
JCJae Yeong Cho
Jae Yeong Cho
KKKye Hun Kim
Kye Hun Kim
HYHyun Ju Yoon
Hyun Ju Yoon
HSHyun Ju Seon
Hyun Ju Seon
YAYoungkeun Ahn
Youngkeun Ahn
JPJong Chun Park
Jong Chun Park
Cho JY, et al. J Korean Med Sci. 2015 Sep;30(9):1361-1366. https://doi.org/10.3346/jkms.2015.30.9.1361

1 January 2011 in International Heart Journal
Verified
Journal Article
Open access
PDF file
MKMin Chul Kim
Min Chul Kim
YAYoungkeun Ahn
Youngkeun Ahn
KCKyung Hun Cho
Kyung Hun Cho
MLMin Goo Lee
Min Goo Lee
JKJum Suk Ko
Jum Suk Ko
JKJung Chaee Kang
Jung Chaee Kang
HMG-CoA reductase inhibitors (statins) reduce major adverse cardiac events (MACE) and mortality in patients with acute coronary syndrome. We investigated whether early statin therapy would be effective at reducing MACE in patients with acute myocardial infarction (AMI). A total of 1,159 patients were analyzed. They were grouped by initiation time of statin administration after admission as follows: group I; n = 945, ≤ 48 hours, group II; n = 214, > 48 hours. Cardiovascular risk factors and noncardiac comorbidities were not different between the two groups. ST-elevation MI as initial diagnosis was more prevalent in group I (68.4% versus 59.3%, P = 0.013). In-hospital mortality was not different in the two groups (0.8% versus 0.5%, P = 0.483). In one-year clinical follow-up, MACE and repercutaneous coronary intervention were lower in group I (17.8% versus 24.6%, P = 0.016, 10.2% versus 15.5%, P = 0.021, respectively). However, there was no difference in mortality (3.8% versus 4.7%, P = 0.319). In multivariate analysis, statin initiation within 48 hours after admission was an independent predictor of one-year MACE (OR 1.49, 95% CI = 1.00-2.21, P = 0.045). Consequently, early statin therapy within 48 hours after admission reduced MACE at one-year follow-up in patients with AMI.